Does anti-VEGF bevacizumab improve survival in experimental sepsis?

Crit Care. 2017 Jul 5;21(1):163. doi: 10.1186/s13054-017-1734-x.

Authors

Emmanuel Besnier^{1

2}, Ebba Brakenhielm³, Vincent Richard³, Fabienne Tamion^{3

4}

Affiliations

¹ Normandie Univ, UNIROUEN, INSERM U1096, 76000, Rouen, France. emmanuel.besnier@chu-rouen.fr.
² Department of Anaesthesia and Critical Care, Rouen University Hospital, 76000, Rouen, France. emmanuel.besnier@chu-rouen.fr.
³ Normandie Univ, UNIROUEN, INSERM U1096, 76000, Rouen, France.
⁴ Medical Critical Care Unit, Rouen University Hospital, 76000, Rouen, France.

No abstract available

Publication types

Letter
Comment

MeSH terms

Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Bevacizumab*
Humans
Sepsis
Vascular Endothelial Growth Factor A*

Substances

Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Vascular Endothelial Growth Factor A
Bevacizumab